November 25, 2020

gettyimages-137418428-rf-hg
Cardiology
Diabetes

AHA: Sotagliflozin Beneficial for T2DM With Heart Failure

WEDNESDAY, Nov. 25, 2020 (HealthDay News) — Sotagliflozin is beneficial for the treatment of type 2 diabetes in patients with recent worsening heart failure as well as in patients with chronic kidney disease, according to two studies published online Nov. 16 in the New England Journal of Medicine to coincide with the American Heart Association...

Stay informed on the latest health disparities research, cultural sensitivity education, and how you can help improve patient outcomes.
This field is for validation purposes and should be left unchanged.